Trial · NCT02413372
Results by group90
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 90
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Mean Change in Percent Hepatic Fat Fraction (%) by Magnetic Resonance Imaging (MRI) From Baseline to Week 16 | BMS-986036 10 mg QD | Day 57 | -8.43 | 90% Confidence Interval -9.81 to -7.06 | percentage |
| Mean Change in Percent Hepatic Fat Fraction (%) by Magnetic Resonance Imaging (MRI) From Baseline to Week 16 | BMS-986036 20 mg QW | Day 57 | -6.45 | 90% Confidence Interval -7.90 to -5.00 | percentage |
| Mean Change in Percent Hepatic Fat Fraction (%) by Magnetic Resonance Imaging (MRI) From Baseline to Week 16 | Placebo QD | Day 57 | -1.26 | 90% Confidence Interval -2.58 to 0.06 | percentage |
| Mean Change in Percent Hepatic Fat Fraction (%) by Magnetic Resonance Imaging (MRI) From Baseline to Week 16 | BMS-986036 10 mg QD | Day 112 | -6.77 | 90% Confidence Interval -8.64 to -4.91 | percentage |
| Mean Change in Percent Hepatic Fat Fraction (%) by Magnetic Resonance Imaging (MRI) From Baseline to Week 16 | BMS-986036 20 mg QW | Day 112 | -5.20 | 90% Confidence Interval -7.13 to -3.26 | percentage |
| Mean Change in Percent Hepatic Fat Fraction (%) by Magnetic Resonance Imaging (MRI) From Baseline to Week 16 | Placebo QD | Day 112 | -1.35 | 90% Confidence Interval -3.13 to 0.43 | percentage |
| Number of Participants With Adverse Events (AEs) | BMS-986036 10 mg QD | 18 | Participants | ||
| Number of Participants With Adverse Events (AEs) | BMS-986036 20 mg QW | 13 | Participants | ||
| Number of Participants With Adverse Events (AEs) | Placebo QD | 15 | Participants | ||
| Number of Participants With Serious Adverse Events (SAEs) | BMS-986036 10 mg QD | 1 | Participants | ||
| Number of Participants With Serious Adverse Events (SAEs) | BMS-986036 20 mg QW | 0 | Participants | ||
| Number of Participants With Serious Adverse Events (SAEs) | Placebo QD | 1 | Participants | ||
| Number of Participants With Injection Site Reactions | BMS-986036 10 mg QD | Injection Site Bruising | 2 | Participants | |
| Number of Participants With Injection Site Reactions | BMS-986036 20 mg QW | Injection Site Bruising | 2 | Participants | |
| Number of Participants With Injection Site Reactions | Placebo QD | Injection Site Bruising | 0 | Participants | |
| Number of Participants With Injection Site Reactions | BMS-986036 10 mg QD | Injection Site Erythema | 1 | Participants | |
| Number of Participants With Injection Site Reactions | BMS-986036 20 mg QW | Injection Site Erythema | 1 | Participants | |
| Number of Participants With Injection Site Reactions | Placebo QD | Injection Site Erythema | 1 | Participants | |
| Number of Participants With Injection Site Reactions | BMS-986036 10 mg QD | Injection Site Reaction | 1 | Participants | |
| Number of Participants With Injection Site Reactions | BMS-986036 20 mg QW | Injection Site Reaction | 1 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02413372/results